Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024
Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has announced an upcoming oral presentation at the 21st International Congress of the Society for Melanoma Research. The presentation will feature updated clinical data on the company's lead cell therapy candidate, ACTengine® IMA203, which targets PRAME in PD1-refractory metastatic melanoma.
The presentation is scheduled for October 11, 2024, from 8:00 to 8:20 am CDT, during the Plenary Session 1 on Developmental Immunotherapy. Dr. Martin Wermke from the University Hospital Dresden, Germany, will deliver the presentation titled 'ACTengine IMA203 TCR-T targeting PRAME in PD1-refractory metastatic melanoma – Clinical Update'.
Immatics N.V. (NASDAQ: IMTX), un'azienda biofarmaceutica in fase clinica specializzata in immunoterapie contro il cancro che ridirezionano le cellule T, ha annunciato una prossima presentazione orale al 21° Congresso Internazionale della Società per la Ricerca sul Melanoma. La presentazione presenterà dati clinici aggiornati sul candidato principale della terapia cellulare dell'azienda, ACTengine® IMA203, che mira a PRAME nel melanoma metastatico refrattario a PD1.
La presentazione è programmata per l'11 ottobre 2024, dalle 8:00 alle 8:20 CST, durante la Sessione Plenaria 1 sull'Immunoterapia Sperimentale. Il Dr. Martin Wermke dell'Ospedale Universitario di Dresda, Germania, terrà la presentazione intitolata 'ACTengine IMA203 TCR-T che mira a PRAME nel melanoma metastatico refrattario a PD1 – Aggiornamento Clinico'.
Immatics N.V. (NASDAQ: IMTX), una compañía biofarmacéutica en etapa clínica enfocada en inmunoterapias contra el cáncer que redirigen células T, ha anunciado una próxima presentación oral en el 21° Congreso Internacional de la Sociedad para la Investigación del Melanoma. La presentación contará con datos clínicos actualizados sobre el candidato principal de la terapia celular de la compañía, ACTengine® IMA203, que se dirige a PRAME en melanoma metastático refractario a PD1.
La presentación está programada para el 11 de octubre de 2024, de 8:00 a 8:20 am CDT, durante la Sesión Plenaria 1 sobre Inmunoterapia en Desarrollo. El Dr. Martin Wermke del Hospital Universitario de Dresde, Alemania, dará la presentación titulada 'ACTengine IMA203 TCR-T dirigido a PRAME en melanoma metastático refractario a PD1 – Actualización Clínica'.
Immatics N.V. (NASDAQ: IMTX)는 T 세포를 재지향하는 암 면역 요법에 집중하는 임상 단계의 생물 제약 회사로, 제21회 국제 흑색종 연구 학회에 대한 구두 발표가 예정되어 있다고 발표했습니다. 이 발표는 회사의 주요 세포 치료 후보인 ACTengine® IMA203에 대한 업데이트된 임상 데이터를 선보일 것이며, 이 후보는 PD1 내성 전이성 흑색종의 PRAME을 표적으로 합니다.
발표는 2024년 10월 11일 오전 8:00부터 8:20까지 CDT로 계획되어 있으며, 개발 면역 요법에 관한 제1회 총회에서 진행됩니다. 독일 드레스덴 대학교 병원의 Dr. Martin Wermke가 'PD1 내성 전이성 흑색종의 PRAME을 표적으로 하는 ACTengine IMA203 TCR-T – 임상 업데이트'라는 제목의 발표를 진행합니다.
Immatics N.V. (NASDAQ: IMTX), une entreprise biopharmaceutique en phase clinique spécialisée dans les immunothérapies anti-cancer redirigeant les cellules T, a annoncé une prochaine présentation orale lors du 21e Congrès International de la Société de Recherche sur le Mélanome. La présentation mettra en avant des données cliniques mises à jour sur le candidat principal de l'entreprise en thérapie cellulaire, ACTengine® IMA203, qui cible PRAME dans le mélanome métastatique réfractaire au PD1.
La présentation est prévue pour le 11 octobre 2024, de 8h00 à 8h20 CDT, lors de la Séance Plénière 1 sur l'Immunothérapie Développementale. Le Dr. Martin Wermke de l'Hôpital Universitaire de Dresde, en Allemagne, fera une présentation intitulée 'ACTengine IMA203 TCR-T ciblant PRAME dans le mélanome métastatique réfractaire au PD1 – Mise à Jour Clinique'.
Immatics N.V. (NASDAQ: IMTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf T-Zell-umlenkende Krebsimmuntherapien spezialisiert hat, hat eine bevorstehende mündliche Präsentation auf dem 21. Internationalen Kongress der Gesellschaft für Melanomforschung angekündigt. Die Präsentation wird aktualisierte klinische Daten zu dem Hauptkandidaten für die Zelltherapie des Unternehmens, ACTengine® IMA203, präsentieren, der PRAME bei PD1-refraktärem metastatischem Melanom anvisiert.
Die Präsentation ist für den 11. Oktober 2024 von 8:00 bis 8:20 Uhr CDT während der Plenarsitzung 1 zur Entwicklungsimmuntherapie angesetzt. Dr. Martin Wermke vom Universitätsklinikum Dresden, Deutschland, wird die Präsentation mit dem Titel 'ACTengine IMA203 TCR-T, das PRAME bei PD1-refraktärem metastatischem Melanom anvisiert – Klinisches Update' halten.
- Immatics will present updated clinical data on its lead cell therapy candidate ACTengine® IMA203
- The presentation will be featured in a plenary session at a major melanoma research congress
- IMA203 targets PRAME in PD1-refractory metastatic melanoma, addressing a significant unmet medical need
- None.
Houston, Texas and Tuebingen, Germany, September 06, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that updated clinical data on its lead cell therapy candidate, ACTengine® IMA203 targeting PRAME, will be presented at the 21st International Congress of the Society for Melanoma Research.
Oral presentation
Date / Time: October 11, 2024 / 8:00 – 8:20 am Central Daylight Time
Session: Plenary Session 1 – Developmental Immunotherapy (Cellular Immunotherapy, Vaccines, and New Checkpoints)
Title: ACTengine IMA203 TCR-T targeting PRAME in PD1-refractory metastatic melanoma – Clinical Update
Presenter: Martin Wermke, M.D. (University Hospital Dresden, Germany)
About IMA203
ACTengine® IMA203 T cells is an autologous T cell product with a genetically modified, pairing-enhanced TCR directed against an HLA-A*02-presented peptide derived from preferentially expressed antigen in melanoma (PRAME). This peptide is frequently expressed in a large variety of solid cancers, thereby supporting the program’s potential to address a broad cancer patient population. Immatics’ PRAME peptide is present at a high copy number per tumor cell and is homogeneously and specifically expressed in tumor tissue. The peptide has been identified and characterized by Immatics’ proprietary mass spectrometry-based target discovery platform, XPRESIDENT®. Through its proprietary TCR discovery and engineering platform XCEPTOR®, Immatics has generated a highly specific T cell receptor (TCR) against this target for its TCR-based cell therapy approach, ACTengine® IMA203.
ACTengine® IMA203 TCR-T is currently being evaluated in a Phase 1 trial as IMA203 monotherapy, and as a second-generation IMA203CD8 (GEN2) monotherapy, where IMA203-engineered T cells are co-transduced with a CD8αβ co-receptor, thereby leveraging the power of both CD4+ and CD8+ T cells. As previously reported, IMA203 in combination with an immune checkpoint inhibitor has been deprioritized.
About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates you can also follow us on X, Instagram and LinkedIn.
For more information, please contact:
| Media | |
| Trophic Communications | |
| Phone: +49 171 3512733 | |
| immatics@trophic.eu |
| Immatics N.V. | |
| Jordan Silverstein | |
| Head of Strategy | |
| Phone: +1 346 319-3325 | |
| InvestorRelations@immatics.com |
Attachment
FAQ
When and where will Immatics (IMTX) present its updated clinical data on ACTengine® IMA203?
What is the target of Immatics' (IMTX) ACTengine® IMA203 therapy?
Who will present the clinical update on Immatics' (IMTX) ACTengine® IMA203?
What type of therapy is Immatics (IMTX) developing with ACTengine® IMA203?
